A brain-enriched polypyrimidine tract-binding protein antagonizes the ability of Nova to regulate neuron-specific alternative splicing.

The Nova paraneoplastic antigens are neuron-specific RNA binding proteins that participate in the control of alternative splicing. We have used the yeast two-hybrid system to isolate Nova interacting proteins and identify an RNA binding protein that is closely related to the polypyrimidine tract-binding protein (PTB). The expression of this protein, brPTB, is enriched in the brain, where it is expressed in glia and neurons. brPTB interacts with Nova proteins in cell lines and colocalizes with Nova within neuronal nuclei. We previously found that Nova binds to a pyrimidine-rich RNA element present upstream of an alternatively spliced exon, E3A, in glycine receptor alpha2 (GlyRalpha2) pre-mRNA, and this binding is implicated in Nova-dependent regulation of splicing. Cotransfection assays with a GlyRalpha2 minigene demonstrate that brPTB antagonizes the action of Nova to increase utilization of GlyRalpha2 E3A. brPTB binds to a 90-nt GlyRalpha2 RNA adjacent to the Nova binding site, but with an affinity that is more than 10-fold lower than Nova. When a putative binding site for brPTB on the GlyRalpha2 RNA is mutated, binding is abolished and the inhibitory effect on Nova-dependent exon selection disappears. These results suggest that brPTB is a tissue-restricted RNA binding protein that interacts with and inhibits the ability of Nova to activate exon selection in neurons.

[1]  R. Darnell,et al.  Nova, the paraneoplastic Ri antigen, is homologous to an RNA-binding protein and is specifically expressed in the developing motor system , 1993, Neuron.

[2]  A. Krainer,et al.  Regulation of alternative splicing in vivo by overexpression of antagonistic splicing factors. , 1994, Science.

[3]  P. Sharp,et al.  Characterization of cDNAs encoding the polypyrimidine tract-binding protein. , 1991, Genes & development.

[4]  Douglas L. Black,et al.  hnRNP H Is a Component of a Splicing Enhancer Complex That Activates a c-src Alternative Exon in Neuronal Cells , 1999, Molecular and Cellular Biology.

[5]  P. Grabowski.  Splicing Regulation in Neurons: Tinkering with Cell-Specific Control , 1998, Cell.

[6]  M. Ashiya,et al.  A neuron-specific splicing switch mediated by an array of pre-mRNA repressor sites: evidence of a regulatory role for the polypyrimidine tract binding protein and a brain-specific PTB counterpart. , 1997, RNA.

[7]  R. Darnell,et al.  Sequence-Specific RNA Binding by a Nova KH Domain Implications for Paraneoplastic Disease and the Fragile X Syndrome , 2000, Cell.

[8]  C. H. Lin,et al.  Regulation of alternative 3' splice site selection by constitutive splicing factors. , 1995, RNA.

[9]  R. Darnell,et al.  The neuronal RNA-binding protein Nova-2 is implicated as the autoantigen targeted in POMA patients with dementia. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[10]  R. Darnell,et al.  The cytoplasmic Purkinje onconeural antigen cdr2 down-regulates c-Myc function: implications for neuronal and tumor cell survival. , 1999, Genes & development.

[11]  G. Dreyfuss,et al.  The SMN–SIP1 Complex Has an Essential Role in Spliceosomal snRNP Biogenesis , 1997, Cell.

[12]  D L Black,et al.  A complex intronic splicing enhancer from the c-src pre-mRNA activates inclusion of a heterologous exon , 1997, Molecular and cellular biology.

[13]  Michael R. Green,et al.  The protein Sex-lethal antagonizes the splicing factor U2AF to regulate alternative splicing of transformer pre-mRNA , 1993, Nature.

[14]  S. Heinemann,et al.  Zinc potentiates agonist-lnduced currents at certain splice variants of the NMDA receptor , 1993, Neuron.

[15]  A. Krainer,et al.  Mechanisms for selecting 5' splice sites in mammalian pre-mRNA splicing. , 1994, Trends in genetics : TIG.

[16]  T Pawson,et al.  The Clk/Sty protein kinase phosphorylates SR splicing factors and regulates their intranuclear distribution. , 1996, The EMBO journal.

[17]  R. C. Chan,et al.  The polypyrimidine tract binding protein binds upstream of neural cell-specific c-src exon N1 to repress the splicing of the intron downstream , 1997, Molecular and cellular biology.

[18]  R. Huganir,et al.  Splice Variant-Specific Interaction of the NMDA Receptor Subunit NR1 with Neuronal Intermediate Filaments , 1998, The Journal of Neuroscience.

[19]  Robert B Darnell,et al.  Nova-1 Regulates Neuron-Specific Alternative Splicing and Is Essential for Neuronal Viability , 2000, Neuron.

[20]  M. Rosenfeld,et al.  Alternative production of calcitonin and CGRP mRNA is regulated at the calcitonin-specific splice acceptor , 1989, Nature.

[21]  K. White,et al.  The Neuron-Enriched Splicing Pattern ofDrosophila erect wing Is Dependent on the Presence of ELAV Protein , 2000, Molecular and Cellular Biology.

[22]  C. Gooding,et al.  Polypyrimidine Tract Binding Protein Functions as a Repressor To Regulate Alternative Splicing of α-Actinin Mutally Exclusive Exons , 1999, Molecular and Cellular Biology.

[23]  M. Ruegg,et al.  cDNA that encodes active agrin , 1992, Neuron.

[24]  D. Black.  Activation of c-src neuron-specific splicing by an unusual RNA element in vivo and in vitro , 1992, Cell.

[25]  J. Valcárcel,et al.  Post-transcriptional regulation: The dawn of PTB , 1997, Current Biology.

[26]  R. Darnell,et al.  The neuronal RNA binding protein Nova-1 recognizes specific RNA targets in vitro and in vivo , 1997, Molecular and cellular biology.

[27]  J. Valcárcel,et al.  Distinct binding specificities and functions of higher eukaryotic polypyrimidine tract-binding proteins. , 1995, Science.

[28]  J. Steitz,et al.  Overexpression of HuR, a nuclear–cytoplasmic shuttling protein, increases the in vivo stability of ARE‐containing mRNAs , 1998, The EMBO journal.

[29]  P. Grabowski,et al.  Coordinate repression of a trio of neuron-specific splicing events by the splicing regulator PTB. , 1999, RNA.

[30]  RJ Buckanovich,et al.  The onconeural antigen Nova-1 is a neuron-specific RNA-binding protein, the activity of which is inhibited by paraneoplastic antibodies , 1996, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[31]  I. Pérez,et al.  Mutation of PTB binding sites causes misregulation of alternative 3' splice site selection in vivo. , 1997, RNA.

[32]  M. Ashiya,et al.  Essential nucleotides direct neuron-specific splicing of gamma 2 pre-mRNA. , 1996, RNA.

[33]  B. Sakmann,et al.  Flip and flop: a cell-specific functional switch in glutamate-operated channels of the CNS. , 1990, Science.

[34]  Michael G. Rosenfeld,et al.  Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products , 1982, Nature.

[35]  H. Lou,et al.  An intron enhancer recognized by splicing factors activates polyadenylation. , 1996, Genes & development.

[36]  G. Dreyfuss,et al.  hnRNP I, the polypyrimidine tract-binding protein: distinct nuclear localization and association with hnRNAs. , 1992, Nucleic acids research.

[37]  R. Huganir,et al.  Regulated subcellular distribution of the NR1 subunit of the NMDA receptor. , 1995, Science.

[38]  P. Grabowski.  Genetic Evidence for a Nova Regulator of Alternative Splicing in the Brain , 2000, Neuron.

[39]  D. Black,et al.  Combinatorial control of a neuron-specific exon. , 1999, RNA.

[40]  D L Black,et al.  A new regulatory protein, KSRP, mediates exon inclusion through an intronic splicing enhancer. , 1997, Genes & development.

[41]  D. Matthews,et al.  The splicing factor‐associated protein, p32, regulates RNA splicing by inhibiting ASF/SF2 RNA binding and phosphorylation , 1999, The EMBO journal.

[42]  D. Helfman,et al.  Polypyrimidine Tract-Binding Protein Positively Regulates Inclusion of an Alternative 3′-Terminal Exon , 1999, Molecular and Cellular Biology.

[43]  Lin Jin,et al.  Aberrant RNA Processing in a Neurodegenerative Disease: the Cause for Absent EAAT2, a Glutamate Transporter, in Amyotrophic Lateral Sclerosis , 1998, Neuron.